{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Event&page=64",
    "query": {
      "intervention": "Event",
      "page": 64
    },
    "page_size": 10
  },
  "pagination": {
    "page": 64,
    "page_size": 10,
    "total_count": 2913,
    "total_pages": 292,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Event&page=65&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Event&page=63&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-07T19:26:19.683Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01696877",
      "title": "A Neoadjuvant Study of Androgen Ablation Combined With Cyclophosphamide and GVAX Vaccine for Localized Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer Adenocarcinoma in Situ"
      ],
      "interventions": [
        {
          "name": "degarelix acetate",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "GVAX",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "21 Years and older · Male only"
      },
      "enrollment_count": 29,
      "start_date": "2013-01-18",
      "completion_date": "2018-12-18",
      "has_results": true,
      "last_update_posted_date": "2019-03-28",
      "last_synced_at": "2026-11-07T19:26:19.683Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01696877"
    },
    {
      "nct_id": "NCT02178995",
      "title": "Methylphenidate Treatment of Attention Deficits in Epilepsy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Epilepsy",
        "Cognitive Deficits",
        "Attention Deficits"
      ],
      "interventions": [
        {
          "name": "Methylphenidate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kimford Jay Meador",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 55,
      "start_date": "2014-08",
      "completion_date": "2015-12",
      "has_results": true,
      "last_update_posted_date": "2017-05-30",
      "last_synced_at": "2026-11-07T19:26:19.683Z",
      "location_count": 1,
      "location_summary": "Palo Alto, California",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02178995"
    },
    {
      "nct_id": "NCT04229758",
      "title": "Restarting Anticoagulation After Traumatic Intracranial Hemorrhage",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hemorrhage",
        "Intracranial Hemorrhages",
        "Bleeding",
        "Trauma"
      ],
      "interventions": [
        {
          "name": "Anticoagulants",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Texas at Austin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1100,
      "start_date": "2021-10",
      "completion_date": "2027-02",
      "has_results": false,
      "last_update_posted_date": "2021-05-19",
      "last_synced_at": "2026-11-07T19:26:19.683Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04229758"
    },
    {
      "nct_id": "NCT06754852",
      "title": "A Study Assessing HMB-002 in Participants With Von Willebrand Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Von Willebrand Disease (VWD)",
        "Von Willebrand Disease (VWD), Type 1",
        "Von Willebrand Disease (VWD), Type 2",
        "Von Willebrand Disease (VWD), Type 3"
      ],
      "interventions": [
        {
          "name": "HMB-002 (Part A)",
          "type": "DRUG"
        },
        {
          "name": "HMB-002 (Part B)",
          "type": "DRUG"
        },
        {
          "name": "HMB-002 with Concomitant Factor Concentrate (Part C) (Not Applicable in US)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hemab ApS",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "69 Years",
        "sex": "ALL",
        "summary": "16 Years to 69 Years"
      },
      "enrollment_count": 108,
      "start_date": "2025-02-06",
      "completion_date": "2027-07",
      "has_results": false,
      "last_update_posted_date": "2026-06-30",
      "last_synced_at": "2026-11-07T19:26:19.683Z",
      "location_count": 13,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 10 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06754852"
    },
    {
      "nct_id": "NCT01315626",
      "title": "Bronchiectasis: Evaluation of an Educational Intervention",
      "overall_status": "WITHDRAWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Bronchiectasis"
      ],
      "interventions": [
        {
          "name": "Primary Care Educational event",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Hill-Rom",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2011-01",
      "completion_date": "2011-02",
      "has_results": false,
      "last_update_posted_date": "2015-03-18",
      "last_synced_at": "2026-11-07T19:26:19.683Z",
      "location_count": 1,
      "location_summary": "Shelbyville, Tennessee",
      "locations": [
        {
          "city": "Shelbyville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01315626"
    },
    {
      "nct_id": "NCT05605756",
      "title": "BOTOX Effects on Seizure Severity and Susceptibility",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Drug-resistant Focal Seizure"
      ],
      "interventions": [
        {
          "name": "OnabotulinumtoxinA 145 UNT [Botox]",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Beth Israel Deaconess Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 3,
      "start_date": "2023-03-01",
      "completion_date": "2024-12-01",
      "has_results": true,
      "last_update_posted_date": "2026-06-29",
      "last_synced_at": "2026-11-07T19:26:19.683Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05605756"
    },
    {
      "nct_id": "NCT02824666",
      "title": "Study to Evaluate D2 Receptor Occupancy Following Single Intravenous Administration of ATI-9242",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "ATI-9242",
          "type": "DRUG"
        },
        {
          "name": "[18F]Fallypride Imaging",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Braeburn Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "MALE",
        "summary": "18 Years to 50 Years · Male only"
      },
      "enrollment_count": 7,
      "start_date": "2016-06-20",
      "completion_date": "2016-11-08",
      "has_results": false,
      "last_update_posted_date": "2017-07-17",
      "last_synced_at": "2026-11-07T19:26:19.683Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02824666"
    },
    {
      "nct_id": "NCT04192266",
      "title": "Estrogen and Fear in PTSD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "PTSD"
      ],
      "interventions": [
        {
          "name": "Estradiol",
          "type": "DRUG"
        },
        {
          "name": "Placebo oral tablet",
          "type": "DRUG"
        },
        {
          "name": "Prolonged Exposure (PE) therapy",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "The University of Texas Health Science Center, Houston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 83,
      "start_date": "2020-06-24",
      "completion_date": "2024-12-02",
      "has_results": true,
      "last_update_posted_date": "2026-01-09",
      "last_synced_at": "2026-11-07T19:26:19.683Z",
      "location_count": 2,
      "location_summary": "Philadelphia, Pennsylvania • Houston, Texas",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04192266"
    },
    {
      "nct_id": "NCT03630809",
      "title": "Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "HER2-positive Breast Cancer",
        "HER-2 Gene Amplification",
        "HER2 Positive Breast Carcinoma",
        "HER-2 Protein Overexpression",
        "Breast Cancer, Male",
        "Breast Cancer Female"
      ],
      "interventions": [
        {
          "name": "HER2 DC1 Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2019-01-10",
      "completion_date": "2022-04-11",
      "has_results": false,
      "last_update_posted_date": "2022-04-25",
      "last_synced_at": "2026-11-07T19:26:19.683Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03630809"
    },
    {
      "nct_id": "NCT01313663",
      "title": "A Study to Evaluate Pazopanib in Comparison to Pemetrexed in Maintenance Setting in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) Population",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lung Cancer, Small Cell"
      ],
      "interventions": [
        {
          "name": "pazopanib",
          "type": "DRUG"
        },
        {
          "name": "pemetrexed",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2011-02",
      "completion_date": "2012-07",
      "has_results": true,
      "last_update_posted_date": "2014-10-27",
      "last_synced_at": "2026-11-07T19:26:19.683Z",
      "location_count": 25,
      "location_summary": "Tucson, Arizona • Skokie, Illinois • Indianapolis, Indiana + 19 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Skokie",
          "state": "Illinois"
        },
        {
          "city": "Skokie",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Ames",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01313663"
    }
  ]
}